Trial site

Shanghai General Hospital

Shanghai, 200080, ChinaShanghai First People's Hospital

114running trials
23closed trials

Part of

Shanghai First People's Hospital

“Shanghai General Hospital” is one of the names under which trial registries list Shanghai First People's Hospital. Together they cover 24 sites; the figures below count all of them.

195trials across all its sites
158of them running
24registry sites and names
16,847publications (OpenAlex)

Type (ROR): Healthcare
Website: firsthospital.cn
Publishes most on: Diabetic eye disease
Gastric and oesophageal cancer
Macular degeneration
Glaucoma
Spinal cord injury
Retinitis pigmentosa

See all 195 trials at Shanghai First People's Hospital

Institution data from ROR and OpenAlex, trial counts from the trial registries.

The trials here

What the 139 trials at this site are about, from their registry records.

Conditions: Macular degeneration13 trials
Prostate cancer11 trials
Gastric and oesophageal cancer9 trials
Pancreatic cancer9 trials
Asthma8 trials
Childhood cancers7 trials
Diabetic eye disease7 trials
Bronchiectasis4 trials
Colorectal cancer4 trials
Heart failure4 trials
Lung cancer4 trials
Metastatic breast cancer4 trials
and 42 more
Phase: Phase 351 trials
Phase 227 trials
Phase 113 trials
Phase 1/28 trials
Early phase 16 trials
Phase 2/34 trials
Phase 41 trial
Status: Recruiting54 trials
Active, not recruiting30 trials
Not yet recruiting29 trials
Completed22 trials
Suspended2 trials
Enrolling by invitation1 trial
Terminated1 trial
Lead sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine28 trials
Boehringer Ingelheim10 trials
Eli Lilly and Company6 trials
Innostellar Biotherapeutics Co.,Ltd6 trials
Pfizer5 trials
and 62 more

Running trials

Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
NCT07789184· Phase 3· Hua Huang, MD, PhD· Source
Contact: yuan fang
Not yet recruiting
A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo
NCT07865312· Phase 3· Dermavon Holdings Limited· Source
Contact: Zhouwei Wu
Not yet recruiting
A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic Cancer
NCT07928362· Ruijin Hospital· Source
Contact: jiang long
Recruiting
Sonrotoclax Plus Azacitidine in Patients With MDS-IB2
NCT07885397· Phase 1/2· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source
Contact: Shuang Li
Not yet recruiting
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion
NCT07817615· Phase 1· Changchun GeneScience Pharmaceutical Co., Ltd.· Source
Contact: Xiaodong Sun
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245· Phase 2· Eli Lilly and Company· Source
Contact: Min Zhang (principal investigator)
Not yet recruiting
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
NCT07708285· Phase 1/2· Beijing Tiantan Hospital· Source
Contact: Meiqing Lou, MD, PhD
Not yet recruiting
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
NCT07713745· Phase 2· Beijing Tiantan Hospital· Source
Contact: Meiqing Lou, PhD
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
NCT07517042· Shanghai Zhongshan Hospital· Source
Contact: Yufan Wang, MD, PhD
Not yet recruiting
AI vs. Physician for Anti-VEGF Decision-Making: An RCT
NCT07328776· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source
Contact: Huixun Jia, PhD
Recruiting
Subthalamic Nucleus-Targeted Transcranial Temporal Interference Stimulation for Motor and Non-Motor Symptoms in Parkinson's Disease
NCT07625540· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source
Contact: Xiaoying Zhu, MD
Recruiting
CGM for Insulin-Treated T2DM During Post-Discharge Transition
NCT07414277· Shanghai 6th People's Hospital· Source
Contact: Yufan Wang
Recruiting
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC
NCT07863999· Phase 3· Shanghai Pulmonary Hospital, Shanghai, China· Source
Contact: Zheng Ruan, PhD
Recruiting
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
NCT07450599· Phase 2· Bayer· Source
Recruiting
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Zhiwang Song, Doctor
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors
NCT07439120· Early phase 1· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source
Contact: Yan Xing, MD
Not yet recruiting
VAH vs VA in Newly Diagnosed Elderly AML
NCT07469046· Phase 3· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source
Contact: Shanghai Road
Recruiting
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
NCT07548177· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Yingqi Hua, Doctor
Not yet recruiting
Early-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy
NCT07353398· Early phase 1· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source
Contact: Xueying Ding, MD
Recruiting
Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients
NCT07362927· Early phase 1· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source
Contact: Li Su
Not yet recruiting
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma
NCT07436221· Phase 2· Akeso· Source
Contact: Guoqin Wang
Recruiting
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
NCT07434518· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source
Contact: Shanghai General Hospital
Recruiting
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
NCT07317934· Phase 3· Innostellar Biotherapeutics Co.,Ltd· Source
Contact: associate professor
Recruiting
A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure
NCT07265349· Phase 1/2· Tasly Pharmaceutical Group Co., Ltd· Source
Contact: Fanglin Lu
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Janssen Research & Development, LLC· Source
Not yet recruiting
PSMA-PET/MRI-Ultrasound Multimodal Fusion Navigation for Da Vinci Robot-Assisted Radical Prostatectomy: A Randomized Controlled Trial
NCT07272317· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source
Contact: Jing Zhao, Doctor
Recruiting
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
NCT07275840· Phase 2· Innovent Biologics Technology Limited (Shanghai R&D Center)· Source
Contact: Xiaodong Sun, Doctor (principal investigator)
Recruiting
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07244341· Phase 1· Daiichi Sankyo· Source
Active, not recruiting
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE
NCT07245407· AstraZeneca· Source
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173· Phase 2· Eli Lilly and Company· Source
Contact: Min Zhang (principal investigator)
Recruiting
Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors
NCT07229768· Early phase 1· Yan Xing· Source
Contact: Principal Imvestigator
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437· Phase 2/3· Pfizer· Source
Not yet recruiting
A Clinical Study on Alleviating Hemorrhoids-related Symptoms of Pelvic Radiation Therapy
NCT07175584· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source
Contact: Ge Yan
Not yet recruiting
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Min Zhang, Doctor
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
NCT07038382· Phase 2· Shanghai Henlius Biotech· Source
Contact: Qi Jin
Recruiting
Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients
NCT06832774· Phase 2· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source
Contact: Han Professor
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
PGHD-AI Intelligent Model for the Nutritional Assessment and Intervention of Patients After Radical Surgery for Pancreatic Cancer.
NCT07167264· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source
Contact: Jiang Long, MD
Not yet recruiting
A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China
NCT07042113· Phase 1· Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.· Source
Contact: XueYing Ding, Chief Pharmaceutist
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· Phase 3· Amgen· Source
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839· Phase 2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Peking University First Hospital· Source
Contact: Qingwei Du
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581· Phase 2· Pfizer· Source
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）
NCT06908876· Phase 2· Innovent Biologics Technology Limited (Shanghai R&D Center)· Source
Not yet recruiting
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
NCT06922903· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source
Contact: Dong Yuan

Showing 50 of 114.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Pancreatic cancer9 recruiting
Prostate cancer9 recruiting
Asthma6 recruiting
Childhood cancers5 recruiting
Macular degeneration5 recruiting
Diabetic eye disease4 recruiting
Gastric and oesophageal cancer4 recruiting
Heart failure4 recruiting
Acute myeloid leukaemia3 recruiting
Bronchiectasis3 recruiting
Liver and biliary tract cancer3 recruiting
Lung cancer3 recruiting
Myelodysplastic syndromes3 recruiting
Sarcoma3 recruiting
Type 2 diabetes3 recruiting
Acute lymphoblastic leukaemia2 recruiting
COPD2 recruiting
Fatty liver disease (MASLD/MASH)2 recruiting
High blood pressure2 recruiting
Meningioma2 recruiting
Obesity2 recruiting
Aortic stenosis1 recruiting
Atopic dermatitis (eczema)1 recruiting
Bladder cancer1 recruiting
Cervical cancer1 recruiting
Chronic myeloid leukaemia1 recruiting
Colorectal cancer1 recruiting
Coronary artery disease1 recruiting
Familial hypercholesterolaemia1 recruiting
Head and neck cancer1 recruiting
Hepatitis B1 recruiting
IgA nephropathy1 recruiting
Liver cirrhosis1 recruiting
Lupus (SLE)1 recruiting
Neuroendocrine tumours1 recruiting
Osteoporosis1 recruiting
Parkinson disease1 recruiting
Stroke1 recruiting
Type 1 diabetes1 recruiting
Vitiligo1 recruiting

Closed trials

Completed
A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects
NCT06883695· Phase 1· Guangdong Hengrui Pharmaceutical Co., Ltd· Source
Completed
A Trial of HRS-9813 in Healthy Subjects
NCT06821464· Phase 1· Guangdong Hengrui Pharmaceutical Co., Ltd· Source
Completed
Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients
NCT06492031· Vantive Health LLC· Source
Completed
Trial of JYB1904 in Patients With Allergic Asthma
NCT06438757· Phase 2· Jemincare· Source
Completed
A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema
NCT06422507· Phase 3· Bayer· Source
Completed
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
NCT06023095· Phase 1· Eli Lilly and Company· Source
Completed
A Study of Cytomegalovirus Disease Epidemiology in Pediatric and Adult Liver Transplant Recipients in China
NCT05958186· Lin Zhong· Source
Completed
Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients With Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity
NCT06744686· Phase 1· Suzhou HepaThera Biotech Co., Ltd.· Source
Completed
AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
NCT07030595· Phase 3· Alebund Pharmaceuticals· Source
Completed
A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration
NCT05456828· Phase 1/2· Visara, Inc.· Source
Completed
A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
NCT05520177· Phase 3· Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.· Source
Completed
A Study of Multi-electrode Circular Irreversible Electroporation (IRE) Catheter and Multi-Channel IRE Generator in Paroxysmal Atrial Fibrillation (AF)
NCT05552963· Biosense Webster, Inc.· Source
Completed
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
NCT05522231· Phase 2/3· Hutchmed· Source
Completed
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05052801· Phase 3· Amgen· Source
Terminated
Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
NCT04968184· Phase 3· Novo Nordisk A/S· Source
Completed
Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
NCT05003245· Phase 3· Shanghai Henlius Biotech· Source
Completed
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT04697628· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Completed
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
NCT04643470· Phase 2· BeiGene· Source
Completed
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
NCT04423718· Phase 3· Bayer· Source
Completed
SHR0302 and Steroid As First Line Therapy for Chronic GVHD
NCT04146207· Early phase 1· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source
Completed
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029· Phase 3· Daiichi Sankyo· Source
Completed
Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment
NCT04085276· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source
Completed
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
NCT03777657· Phase 3· BeiGene· Source

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error